---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-236658"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2022-09-01T23:59:59+00:00"
generated_at: "2026-06-23T17:42:51.084023+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Inhibikase appoints Gisele Dion to Board, replacing retiring Elizabeth O'Farrell

## Summary
- Elizabeth O'Farrell retired from the Board effective Sep 1, 2022; departure not due to any disagreement.
- Gisele Dion appointed as Class III director effective Sep 1, 2022.
- Dion receives $65k annual cash and a 60,000-share option grant (50% vest each of first two anniversaries).
- Dion previously SVP & CAO at Takeda, CAO at Shire, and board member at Cytek Biosciences.

## SEC filing metadata
- accession: 0001193125-22-236658
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2022-09-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312522236658/0001193125-22-236658-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312522236658/d283919d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-236658
- JSON: https://secwatch.observer/filing/0001193125-22-236658.json
- Plain text: https://secwatch.observer/filing/0001193125-22-236658.txt

## Key facts
- Executive change
  Gisele Dion was appointed as Director at Inhibikase Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Following Ms. O’Farrell’s resignation, on September 1, 2022, the Board appointed Gisele Dion to serve as a Class III member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312522236658/0001193125-22-236658-index.htm
- Executive change
  Elizabeth O’Farrell retired as Director at Inhibikase Therapeutics, Inc..
  - Action: retired
  - Role: Director
  source text: On September 1, 2022, Elizabeth O’Farrell provided notice to the Board of Directors (the “Board”) of Inhibikase Therapeutics, Inc. (the “Company”) of her intention to retire from the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312522236658/0001193125-22-236658-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.